Here's Why Abeona Therapeutics Popped Higher Today

Core Viewpoint - Abeona Therapeutics' stock surged over 25% following strong third-quarter earnings and positive updates regarding its treatment for Recessive Dystrophic Epidermolysis Bullosa (RDEB), Zevaskyn [1][7]. Group 1: Treatment Overview - RDEB is a rare inherited skin disorder with an incidence of 3.05 per million births and a prevalence of 1.35 per million, leading to a high mortality rate among sufferers due to complications [2]. - Zevaskyn is a gene therapy derived from a patient's own skin, modified to produce a healthy collagen gene, and applied to wounds [3]. Group 2: Patient and Coverage Updates - Management identified 30 patients at treatment centers, with 12 patients currently scheduling treatments, indicating strong interest in the therapy among RDEB patients [5]. - Major commercial insurers, including UnitedHealthcare, Cigna, Aetna, Anthem, and most Blue Cross Blue Shield plans, have published policies covering Zevaskyn, enhancing treatment accessibility [5]. Group 3: Market Reaction and Future Outlook - The market has largely ignored a one-quarter delay in treatment initiation due to a resolved issue, with Abeona expected to start patient treatments this quarter [6]. - Significant revenue growth is anticipated in 2026 as treatment progresses [6].